Tumor-infiltrating lymphocyte cell therapy ‘potentially viable’ option for advanced NSCLC

tumor infiltrating lymphocyte cell therapy potentially viable option for advanced nsclc

Sumary of Tumor-infiltrating lymphocyte cell therapy ‘potentially viable’ option for advanced NSCLC:

  • November 16, 2021 2 min read Source/Disclosures Published by: Source: Schoenfeld AJ, et al.
  • Abstract 458. Presented at: Society for Immunotherapy of Cancer Annual Meeting;
  • Back to Healio Nearly a quarter of patients with heavily pretreated non-small cell lung cancer achieved an objective response to an infusion of LN-145, according to study results presented at Society for the Immunotherapy of Cancer Annual Meeting.
  • Abstract 458. Presented at: Society for Immunotherapy of Cancer Annual Meeting;
  • “Most patients with advanced non-small cell lung cancer who are treated with first-line immune checkpoint inhibitors — with our without chemotherapy — develop disease progression,” Adam J.
  • Schoenfeld, MD, medical oncologist and lung cancer specialist at Memorial Sloan Kettering Cancer Center, said during a presentation.
  • “In this setting,” he added, “options that provide deep and durable responses are urgently needed.
  • ” Schoenfeld presented the first safety and efficacy results from cohort 3B of the multicenter phase 2 IOV-COM-202 trial, designed to evaluate autologous TILs for patients with solid tumors.

Want to know more click here go to source.

From -

Close

Site Language


By continuing to use the site, you agree to the use of cookies. more information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close